oral glp 1 inhibitors GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies Oral GLP-1 Agonist Orforglipron Shows

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study reporting one in eight Americans has taken or is currently using the drugs to treat diabetes, heart disease or obesity

The court sided with earlier Delhi High Court rulings that prioritized public access and affordability over patent exclusivity

Hospitalbased pharmaceutical teams often participate in institutional protocols and therapeutic committees, promoting evidencebased use of incretin drugs

Retatrutide is an investigational drug that is not FDA-approved

GLP-1RAs also downregulate the expression of MMPs and tissue inhibitors of MPs (TIMPs) for anti-inflammation [110]